Bile duct cancer is rare, treatment options are limited, and the survival rates are low ... breast cancer with high levels of HER2 expression (known as HER2-positive). In the new trial of ...

In terms of progression-free survival ... 66% in terms of an intracranial response rate is very high and really the highest ...

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

Medicaid expansion improved 2-year survival rates and access to guideline-concordant treatment for patients with HR-negative and HER2-positive breast cancer. The study highlights the role of ...

Bile duct cancer is rare, treatment options are limited, and the survival rates are low ... breast cancer with high levels of HER2 expression (known as HER2-positive). In the new trial of ...

"Breast cancer is far too common, and rates are increasing among ... With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer, Journal of the ...

Trastuzumab duocarmazine (T-Duo) improved progression-free survival ... 2–positive (HER2+) breast cancer. However, ocular toxicity was prevalent, leading to higher discontinuation rates in ...

Drugs aimed at HER2-positive breast cancer may also help ... Bile duct cancer is uncommon, with few treatment options and low survival rates. The trial also indicates that a broader category ...

These studies evaluate the efficacy of evorpacept in combination with pembrolizumab and chemotherapy in frontline head and neck squamous cell carcinoma (HNSCC), with a focus on achieving superior ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Genentech, a member ...

“Breast cancer is far too common, and rates are increasing among ... With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer” is now ...